In an interview with Moneycontrol, Kedar Upadhye, Global Chief Financial Officer of Cipla, talked about the company's strategy going forward.

Revenue is a challenge for us; little concerned about revenue growth: Cipla

India is a sizeable market for us. Our growth story is intact in our core markets. I am not unduly concerned about growth trajectories within our core markets, said Umang Vohra, MD & Global CEO of Cipla.

See limited competition for Pulmicort; expect 3-4 more approvals by FY18-end: Cipla

The US remains the largest market in the world and they look at it as an attractive opportunity, Umang Vohra, MD & Global CEO, Cipla.

Will continue to pursue inorganic growth in India & US: Torrent Pharma

In an interview to CNBC-TV18's Ekta Batra and Vikas Dandekar, the Executive Chairman of Torrent Pharma, Samir Mehta spoke about the rationale behind the deal and where it would take the company in the Indian pharmaceutical market.

New draft pharma policy will reduce risks like generalisation of mkt: JM Financial

In an interview to CNBC-TV18, Anmol Ganjoo, Director of JM Financial Institutional Securities spoke about his latest report on Indian pharmaceutical space. Ganjoo has written on multiple stocks as well as the entire framework of the pharmaceutical space.

Cipla to remain unfazed by Trump's protectionist policy

Umang Vohra of Cipla reasoned that almost 80 percent of the drugs sold by Cipla in the US market are manufactured in the US itself. He said it will not be a challenge to manufacture all its supplies in the US itself if asked to do so by authorities.

Looking for bigger partnership with Cipla: Serum Institute

Adar Poonawala, CEO of Serum Institute, believes that a bigger partnership with Cipla will create a big Indian conglomerate. However, he added that the Cipla promoters currently have no plans for a merger and acquisition.

Indian pharma cos need to step-up safeguards at plants: Handa

In the last five months, plants of nine Indian pharmaceutical companies - Cipla, Dr Reddy‘s, Sun Pharma, Cadila, Lupin and Natco Pharma.- have come under the US Food and Drug Administration (FDA) scanner.

20% of Cipla FY17 revenues to come from US: Chirag Talati

When asked about the Cipla Indore facility, which has come under the USFDA scanner for manufacturing norms violations, Talati reassures that the facility is not a major contributer to Cipla earnings. Hence this news, he feels should not affect sales.

Cipla completes acquisition of US cos InvaGen and Exelan

In an interview with CNBC-TV18, Umang Vohra, COO of Cipla said that the company‘s current growth guidance did not include this merger and it will be a part of it in the next fiscal.

Sub-license for Hepatitis C drug beneficial for patients: Cipla

Jaideep Gogtay, Clinical Head at Cipla pointed out that in India the cost of treatment of Hepatitis C ranges between Rs 75,000 to Rs 1.5 lakh per patient, depending on the type of virus and the intensity.

Cipla to pay for InvaGen, Exelan mostly through own funds

Cipla Global Chief Executive Officer Subhanu Saxena said both acquisitions would add to Cipla's earnings from Day One, and that the acquisition would give the company a strong platform to accelerate growth in US.

Aiming to achieve 70-80% organic growth: Cipla

The pharma major's MD and CEO Subhanu Saxena says the company is aiming at achieving a growth of 70-80 percent growth without making any major acquisitions in the near future.

Consumer health mkt growing at high double digit: Cipla

Calling consumer healthcare to be an exciting space for the company, Chandru Chawla, the head of Cipla, New Ventures says: "Consumer health market in India is upwards of USD 4 billion today and is growing at a very high double digit."

See Rs 400cr increase in top line over next few yrs: Hetero

The company has 20 facilities across the globe with portfolio of more than 200 products in 138 countries.

What a potential Cipla-Serum merger could mean

Billionnaire Cyrus Poonawalla, founder of the world‘s biggest vaccine maker Serum Institute, has told CNBC-TV18 that after the company tied up with drugmaker Cipla to sell its vaccines in Europe late last year, Serum is now exploring the option of merging with it.

Serum Institute in 'initial talks' to explore Cipla merger

After tying up with drugmaker Cipla to market its products last year, the Poonawalla Group's Serum Institute, the world's largest vaccine maker, is considering the option of merging with it.

Sun's margins may reduce to 30-32% post merger: Surajit Pal

As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.

Discussing partnerships, have done in-licensing deals:Cipla

The company's CEO, Subhanu Saxena, in an exclusive conversation with CNBC-TV18's Archana Shukla says the focus is on building the company for the long term.

Aiming growth of USD 3-4 bn by 2020: Cipla

On the days to come, Yusuf Hamied, chairman, Cipla, says the pharma major may open units in foreign countries just like its peers.

Indian mkt needs hostile takeovers: Grant Thornton

Speaking to CNBC-TV18, Harish HV, partner-India Leadership Team,Grant Thornton, says there has been a significant jump in private equity (PE) deals and the interest in outbound deal continues by India Inc.

Cipla mgmt rejig: Time to act as godfather says YK Hamied

Dr.YK Hamied, CMD, Cipla will retire with effect on March 31.Talking to CNBC-TV18 about his retirement plans, YK Hamied, CMD, Cipla says, “We now have built up a very strong senior management team and time has come to let the youngsters‘ takeover.

Cipla eyes South Africa with plans for Cipla Medpro stake

S Radhakrishnan, ED, Cipla explains to CNBC-TV18 that the company is in discussions to acquire a 51 percent stake in Cipla Medpro, South Africa for a consideration of USD 220 million. The acquisition also offers a stake in Cipla Medpro business in South Africa.

Cipla launches anti-malarial drug in India

In an interview to CNBC-TV18, YK Hamied, chairman and managing director of Cipla says, the company is launching an anti-malarial drug in India. "Today, being the World Malaria day, we are launching a new combination drug along with our partners who are based in Geneva called DNDI," he asserts.

Cipla aims for 8-10% revenues this yr; Eyes overseas growth

YK Hamied, the CMD of Cipla is optimistic the pharma major will post a topline growth of 8-10% this fiscal.In an interview to CNBC-TV18, he says he is looking at the company's bottomline increasing by Rs 1,000 crore in FY13.